Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Obexelimab Is In Phase III In IgG4-Related Disease

 
• By Mandy Jackson
Investors. Shareholders, co-owners. Startups and fundraising.
Zenas will increase its headcount by 20% • Source: Shutterstock

More from Financing

More from Business